DCTHDelcath Systems Inc.Signing up patients
Evaluation of the Safety and Efficacy of Treatment w/High Dose Melphalan Given Directly Into the Liver Followed by Treatment w/Approved Cancer Treatment or Approved Cancer Treatment Alone in Patients w/ Metastatic Breast Cancer w/Liver Dominant Disease
Metastatic Breast Cancer in the Liver
0Calmworry score, out of 100
No strong warning signs right now. The score counts warning signs; it is not a prediction.
Why this score
No warning signs right now. That's why the score is 0.
Score over time
- Stage
- Phase 2
- Patients
- 90 (planned)
- Started
- Jan 29, 2026
- Main results expected
- May 2029
- Fully finished
- Aug 2029
- Results posted
- not yet
What counts as success
The trial's main goal(s), called the “primary outcome.”
hPFS
Measured over: assessed through study completion, an average of 2 years
Changes Tremor has spotted
No changes since Tremor started watching this trial.
Show details (technical version)
Score inputs
- none
Raw record changes
- none yet
Trial ID NCT06875128 · record last updated 2026-10-19 · checked 2026-11-09 15:47 UTC